Details of the Drug
General Information of Drug (ID: DMN1XVC)
| Drug Name |
Lutetium Lu 177 dotatate
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate | ||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 4 |
Molecular Weight | 1609.5 | |||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||
| Rotatable Bond Count | 18 | ||||||||||||||||||
| Hydrogen Bond Donor Count | 14 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count | 26 | ||||||||||||||||||
| ADMET Property |
|
||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Neuroendocrine cancer | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2B72.1 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


